DT120 ODT (MM120) lysergide tartrate - (Panorama)
- Indication
- Generalized Anxiety Disorder (GAD)
- Stage
- phase3
- Event
- Topline Data
- Details
August 26, 2026: Definium Therapeutics, Inc. (NASDAQ: DFTX) announced management participation in investor events that will discuss DT120 ODT in generalized anxiety disorder. At a Stifel-hosted virtual fireside chat on September 1, 2026, the company plans to review positive topline results from the Phase 3 Voyage study of DT120 ODT in GAD, including clinical takeaways and implications for the program, and to discuss expectations for the upcoming Phase 3 Panorama topline results, described as the second pivotal study of DT120 ODT in GAD.
Definium will also present at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026, and attend the 2026 Leerink Partners Biopharma Summit from September 23-25, 2026.
The key catalyst highlighted is the pending topline readout from Phase 3 Panorama in GAD.
- Source
- View catalyst source ↗